AB Science in the news
Developing targeted therapies for diseases
Tamtam found 20 recent articles about AB Science.
- 5 biotech françaises appréciées des analystes avec jusqu’à +220% de potentiel
AB Science's stock saw a significant but unexplained surge, yet remains overvalued, highly volatile, and lacking commercial revenue, prompting a recommendation for diversification into more stable biotech options.
- AB Science SA Revenue Breakdown – MUN:A8D
AB Science SA reported 1.10 million EUR in revenue last year, primarily from its Synthetic Therapeutic Molecules segment and France.
- AB Science SA Revenue Breakdown – LSE:0Q77
AB Science SA reported 1.10 million EUR in revenue last year, primarily from its Synthetic Therapeutic Molecules segment and operations in France.
- Forum Bourse AB SCIENCE - 15/07/2026 22:18:21 - AB SCIENCE - le support oblique baissier est touché et .....
The article from Forum Bourse discusses AB Science stock hitting bearish oblique support, with indicators suggesting potential upward movement due to a low RSI and lagging span.
- Developer stops large trial of promising treatment for progressive MS
AB Science discontinued its late-stage clinical trial for masitinib in multiple sclerosis to prioritize development for ALS and acute myeloid leukemia.
- AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
AB Science is halting three non-priority clinical studies to reallocate resources to its two main programs for acute myeloid leukemia and amyotrophic lateral sclerosis.
- AB Science to Discontinue Three Masitinib-related Clinical Studies
AB Science is discontinuing three clinical trials for its drug masitinib due to unfavorable conditions, prioritizing other development programs.
- AB Science ends 3 studies in multiple sclerosis, other immune conditions
AB Science is ending three clinical trials for masitinib in immune-mediated diseases to concentrate resources on its ALS and acute myeloid leukemia programs.
- AB Science fait le point sur son programme clinique avec
AB Science is halting non-priority clinical trials to focus resources on two key programs: AB8939 for acute myeloid leukemia and masitinib for amyotrophic lateral sclerosis.
- AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development
AB Science is restructuring its board to begin a new development phase.
- AB Science recentre son portefeuille sur deux programmes prioritaires
AB Science is refocusing its portfolio by discontinuing three clinical trials to prioritize two key programs: AB8939 for acute myeloid leukemia and masitinib for amyotrophic lateral sclerosis.
- AB Science cuts three trials in pipeline reset
AB Science is discontinuing three masitinib trials and focusing on ALS and AML programs after regulatory concerns and a pipeline reset.
- AB Science rationalise son portefeuille et se recentre sur deux molécules...
AB Science rationalizes its drug portfolio, stopping three non-priority clinical trials to concentrate resources on acute myeloid leukemia and amyotrophic lateral sclerosis.
- AB Science Refocuses Portfolio on Two Priority Programs
AB Science is re-prioritizing its drug development portfolio by stopping three clinical trials to concentrate resources on two main programs: AB8939 for acute myeloid leukemia and masitinib for amyotrophic lateral sclerosis.
- AB Science rationalise son portefeuille et se recentre sur deux molécules
AB Science is rationalizing its portfolio by discontinuing three non-priority clinical studies to reallocate resources to two key molecules for acute myeloid leukemia and amyotrophic lateral sclerosis.
- AB Science provides an update on its clinical program,
AB Science is halting non-priority clinical trials to concentrate resources on its AB8939 program for acute myeloid leukemia and masitinib program for amyotrophic lateral sclerosis.
- AB Science : arrêt de trois études cliniques considérées comme non prioritaires
AB Science is stopping three non-priority clinical trials to focus on its acute myeloid leukemia and amyotrophic lateral sclerosis programs.
- AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs
AB Science is halting three non-priority clinical trials to re-focus resources on its AB8939 program for acute myeloid leukemia and its masitinib program for amyotrophic lateral sclerosis.
- Nomination de Stéphane LEDERMANN en qualité de Président Directeur Général
AB Science appointed Stéphane Ledermann as its new Chairman and CEO to lead a strategic review and guide the company's next development phase.
- AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
AB Science is discontinuing three non-priority clinical trials to reallocate resources to its AB8939 program for acute myeloid leukemia and its masitinib program for amyotrophic lateral sclerosis.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like AB Science?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies